Anuh Pharma Ltd Signs Asset Transfer Agreement for Rs. 72.90 Crore
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 16 Oct 2026, 06:54 PM IST · BSE ID: 95529789-8d58-4d83-a37f-9467aaa7569e
View Original BSE Filing (PDF)
💡
In Simple Terms
Anuh Pharma bought a factory from Vanquest Pharma for Rs. 72.90 Crore to boost its medicine ingredient production.
🤖 AI Summary
- Anuh Pharma Limited (APL) signed an Asset Transfer Agreement to acquire a manufacturing facility from Vanquest Pharma Private Limited (VPPL).
- The acquisition is valued at Rs. 72.90 Crore, excluding applicable taxes and fees, for land, building, plant & machinery.
- The purchase is expected to increase APL's production capacity by 525 MTPA for APIs and intermediates.
- Vanquest Pharma Private Limited was incorporated on 12/06/2019, and APL holds no shareholding in it.
- The transaction is not a related party transaction; the counterparty is not related to APL's promoter group.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Asset Purchase Value
Rs. 72.90 Crore
Production Capacity Increase
525 MTPA
🏢 How This Affects the Company
This acquisition is expected to strengthen Anuh Pharma Limited's market presence in manufacturing quality APIs and intermediates. It directly expands the company's product sourcing capability.
The acquisition involves a cash consideration of Rs. 72.90 Crore, which will impact the company's cash reserves and balance sheet structure. Further financial details regarding funding were not disclosed in the filing.
Anuh Pharma Limited's production capacity for APIs and intermediates is expected to increase by 525 MTPA. This expands the company's manufacturing footprint at the Tarapur, Boisar facility.
The filing does not indicate an increase in specific risks. The transaction is not a related party transaction, mitigating potential governance risks associated with such dealings.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this disclosure.
👤
Who Is Affected
Shareholders are indirectly affected by the company's strategic decision to expand its manufacturing capabilities. The Rs. 72.90 Crore cash outflow for the asset purchase impacts the company's financials.
🔍
Management Signal
Management's decision indicates a focus on strengthening internal production capacity and expanding market presence in the API and intermediates segment.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 financial results — check for cash flow impact of acquisition.
Future disclosures on operational integration of the new facility.
Updates on the actual utilization rate of the expanded 525 MTPA capacity.
LOW RISK
The transaction is not a related party transaction, and no significant risks were flagged in the filing.
💡 Investor Takeaway
Anuh Pharma Limited has signed an Asset Transfer Agreement to acquire a manufacturing facility from Vanquest Pharma Private Limited for Rs. 72.90 Crore. This purchase is intended to increase production capacity by 525 MTPA for APIs and intermediates.
⚖️ Strengths & Concerns
✅ Positives
- Acquisition increases Anuh Pharma's production capacity by 525 MTPA, directly expanding manufacturing capability.
- The transaction is not a related party deal, ensuring independent terms and reducing potential conflict of interest concerns.
⚠️ Concerns
- The filing does not provide details on how the Rs. 72.90 Crore cash consideration will be funded by the company.
- Specific timelines for facility integration and capacity utilization are not detailed in the disclosed agreement terms.
❓ Frequently Asked Questions
What is the value of the Asset Transfer Agreement signed by Anuh Pharma?
Anuh Pharma Limited has signed an Asset Transfer Agreement for the purchase of assets valued at Rs. 72.90 Crore, excluding applicable taxes and fees.
What is the purpose of Anuh Pharma's asset acquisition from Vanquest Pharma Private Limited?
The purpose is to purchase assets (Land, Building, Plant & Machineries, etc.) for manufacturing APIs and Intermediates, strengthening the Company's production capacity and market presence.
How much will Anuh Pharma's production capacity increase due to this acquisition?
The purchase of assets is expected to increase Anuh Pharma Limited's production capacity by 525 MTPA.
Is the transaction with Vanquest Pharma Private Limited a related party transaction?
No, the transaction is not a related party transaction, and Vanquest Pharma Private Limited is not related to Anuh Pharma's promoter/promoter group.
Questions based on this BSE filing only. For information purposes.